SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Neotherapuetics possibly has a breakthrough drug - NEOT
An SI Board Since July 1999
Posts SubjectMarks Bans Symbol
204 15 0 NEOT
Emcee:  Marty Type:  Unmoderated
Introduction Market Data Compact
Here is a company that has completed several phase 2a tests on human patients with Alzheimer's disease. One phase 2b test with 400 AD patients started in February, 1999. All tests so far show that their drug, Neotrofin, is absorbed orally, biologically active within hours, and turns on the genes producing nerve growth factors. Basically, new nerve cells are produced and the memory process regenerated, without regard as to why the old ones failed. All tests thus far confirm same thing, improvement in memory and function. This is not just a slowing of the degenerative process as current drugs on the market seek to accomplish. Other drugs they have in the same family target dementia, spinal cord injury, stroke, and other central nervous system problems. A presentation to the 3rd Annual International Conference on Neurodegeneration is scheduled on July 27, 1999 to present an early evaluation of the drug, based on completed clinical trials. They are at least a year ahead of all other firms in this field.

I submit that the stock, now 15 3/4, and the warrants, now 6 1/4 are the buy of a lifetime.
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
204GPC Biotech Receives Fast Track Designation for Anticancer Drug Candidate SatrapIcebrg-9/22/2003
203I should admit it is very hard to evaluate fair market prce of SPPI at this poinNikole Wollerstein-8/11/2003
202GPC Biotech Q2 report [In their Q2 report GPC Biotech continues to sound optimiIcebrg-8/5/2003
201Spectrum Reports Positive Phase 1 Data; Will Initiate Phase 2 Study of Eoquin(TMIcebrg-6/11/2003
200Spectrum Pharmaceuticals Receives Additional $1.56 Million in Financing WednesdaIcebrg-5/14/2003
199Spectrum Pharmaceuticals Announces FDA Acceptance of ANDA Filing for CiprofloxacIcebrg-5/9/2003
198Spectrum Pharma turns to VCs by Clifford Carlsen Updated 04:46 PM EST, May-8-200Icebrg-5/9/2003
197>>IRVINE, Calif., April 8 /PRNewswire-FirstCall/ -- Spectrum Pharmaceuticatuck-4/8/2003
196From S3 filed today: <i>RECENT DEVELOPMENTS On January 15, 2003, we annoIcebrg-1/17/2003
195Spectrum Pharmaceuticals Announces Filing of First ANDA With the FDA for ApprovaIcebrg-1/15/2003
194>>Might it not have been cheaper for GPC to buy the company ?>> WhyIcebrg-10/1/2002
193Might it not have been cheaper for GPC to buy the company ? Tuesday October 1, nigel bates-10/1/2002
192>>From the charts it looks like the street believes in the science, but thIcebrg-7/12/2002
191I just spent two hours analyzing NEOT charts. From the charts it looks like theXenaLives-7/12/2002
190One has to wonder about the study design. I understand the stock has more than tuck-5/30/2002
189very strange results, Neotrofin(TM) acts by inducing neotrofins but this processNikole Wollerstein-5/30/2002
188Wow. I was tempted a number of times, but never bit on these shares. I make pltuck-5/4/2002
187NeoTherapeutics Investors Right Of First Refusal Expires DOW JONES NEWSWIRES Imopgcw-4/17/2002
186Here's the article: December 13, 2001 Drugs to Spur New Cells, and WithoutJMarcus-12/13/2001
185New York Times article on drugs that stimulate cell regeneration. Prominent menDoc Bones-12/13/2001
184Tuesday November 6, 8:15 am Eastern Time Press Release SOURCE: White Mountain CaGC-11/6/2001
183>>IRVINE, Calif., Sept. 5 /PRNewswire/ -- NeoTherapeutics, Inc. (Nasdaq: Ntuck-9/5/2001
182>>IRVINE, Calif., Sept. 4 /PRNewswire/ -- NeoTherapeutics, Inc. (Nasdaq: Ntuck-9/4/2001
181>>IRVINE, Calif., Aug. 22 /PRNewswire/ -- NeoTherapeutics, Inc. (Nasdaq: Ntuck-8/22/2001
180It is very interesting review about the role of the purines in the brain developNikole Wollerstein-8/13/2001
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News